AlphaCore Aiming High with Recombinant LCAT
By Marie Powers
Thursday, January 3, 2013
AlphaCore Pharma Inc. has maintained a low profile since its founding in 2007, perhaps befitting for a biotech working in the rare orphan indication of familial LCAT deficiency (FLD).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.